Project Grant HT9425261E466
Award Date 9/15/26
Completion Date 9/14/27
Dollars Obligated $839K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newtonville, MA 02458, USA
Similar Awards
- The Defense Health Agency awarded $835,087 to Iris Medicine, Inc. on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support amyotrophic lateral sclerosis research. Performance will take place in Berkeley, California, over a period of performance from November 1, 2026, through October 31, 2028. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for Service Members and...
- The Defense Health Agency awarded $831,722 to Aristotelio Panepistimio Thessalonikis - Eidikos Logariasmos Kondilion Erevnas (Special Account For Research Funds) on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support oxidized-protein targeted degradation as a first-in-class therapeutic strategy to combat oxidative damage in amyotrophic lateral sclerosis (ALS). Performance extends through June 14, 2028, and takes place in Greece. The award funds...
- The Defense Health Agency awarded Yale University $839,991 for research targeting neuronal calcium sensor-1 as a novel therapeutic for amyotrophic lateral sclerosis under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2026. Work will be performed in New Haven, Connecticut through April 30, 2028. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for Service Members and the American...
- The Defense Health Agency awarded Emory University $840,000 on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) for a project repurposing approved drugs as first-in-class disruptors of the P38/MK2 complex to suppress neuroinflammation in amyotrophic lateral sclerosis (ALS). Performance occurs in Atlanta, Georgia, with a period of performance running through March 31, 2028. The award is structured as a project grant under the Defense Health Program's...
- <p>The Defense Health Agency awarded Massachusetts General Hospital $839,954 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop augmented immunomodulatory and neuroprotective allogeneic B cell therapy for amyotrophic lateral sclerosis (ALS). The award runs through May 31, 2028, with work performed at Massachusetts General Hospital's Research Management Division in Boston, Massachusetts. The assistance type is a Project Grant.</p>
- <p>The Defense Health Agency awarded $1.920457 million to Transposon Therapeutics, Inc. on May 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop human Line-1 reverse transcriptase inhibitors for the treatment of amyotrophic lateral sclerosis. The award carries no indirect costs. Work is performed in Laguna Niguel, California, with a period of performance through February 14, 2028.</p>
- The Defense Health Agency awarded the University of Southern California $840,000 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to validate CCDC146 suppression as a therapeutic strategy for diverse forms of amyotrophic lateral sclerosis (ALS). The award, classified as a Project Grant, funds research performed at USC's Los Angeles, California location through July 31, 2028. The Military Medical Research and Development program supports basic, applied,...
- The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
- The Defense Health Agency awarded Novagen Research Fund $1.85 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop short hairpin RNA targeting a human endogenous retrovirus as a therapeutic approach to amyotrophic lateral sclerosis. The award funds basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative and impactful research. Work is performed in North...
- The Defense Health Agency awarded Ephius, Inc., $3.326 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop EPH-ephrin tetramerization inhibitors to combat scleroderma. The award runs through June 30, 2029, with place of performance in Dallas, Texas. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through...